Bone Biologics (BBLG)
Develops an investigational NELL-1 bone-graft candidate for lumbar spinal fusion.
Something off on this page? Send us feedback.
Develops NB1, an investigational NELL-1/DBM graft for lumbar spinal fusion, intended for future sale as a surgeon-prepared convenience kit; it remains a clinical-stage, pre-revenue company.
Develops NB1, an investigational bone-graft candidate that combines recombinant human NELL-1 with demineralized bone matrix for lumbar spinal fusion. The planned convenience kit pairs the vial with diluent and MTF Biologics' DBM Putty for surgeon mixing before implantation.
Runs its first human study in Australia while planning a later U.S. pivotal study and FDA premarket approval. The company operates through two full-time employees and outsourced clinical, regulatory-management, manufacturing, marketing and sales providers.
Holds exclusive UCLA-licensed rights in its defined spinal-fusion, osteoporosis and trauma fields. Product commercialization depends on clinical results, compliant manufacturing, FDA approval, the UCLA license, coverage and reimbursement.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.0M · Total debt $0 · Total assets $4.4M · Shareholders' equity $3.9M
- Revenue
- $0
- Operating income
- −$808.1K
- Net income
- −$773.7K
No dividends on record.
| Institutions3 holders · as of Mar 31, 2026 | 0.16% | 4.4K shares | |
| Otherremainder | 99.84% | 2.75M shares |
2.76M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.76M in the company's Sep 3, 2026 report, 1.81M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Tower Research Capital LLC (TRC)Institution | 0.15% | 4,126 | 13Fas of Mar 31, 2026 |
Sbi Securities Co., Ltd.Institution | 0.01% | 230 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.00% | 56 | 13Fas of Mar 31, 2026 |
Ionic Ventures, LLCStrategic | —9.99% of class, as filed | — | 13G/Afiled Dec 20, 2023 ↗ |
Lind Global Partners II LLCStrategic | —6.50% of class, as filed | — | 13Gfiled Jun 26, 2023 ↗ |
| See all 14 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Medtronic
Approved recombinant graft benchmark for lumbar TLIF.
- Globus Medical
Cellular, DBM and synthetic grafts for spine fusion.
- Stryker
Broad spine biomaterials portfolio across graft substitutes.
- Johnson & Johnson
DePuy Synthes spinal biologics and fusion systems.
- Orthofix Medical
Cellular allograft alternative for lumbar spinal fusion.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bone Biologics | $0.5730 | +1.70% | $996.4K | — | — | — | — |
| Medtronic | $92.50 | +0.33% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Globus Medical | $80.85 | +0.25% | $10.88B | 20.7 | 15.8 | 3.5 | +5.9% |
| Stryker | $315.43 | +1.04% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| Johnson & Johnson | $275.41 | +0.06% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Orthofix Medical | $9.29 | −0.95% | $379.2M | — | — | 0.5 | +3.9% |
| Median | 27.3 | 17.6 | 3.5 | +6.6% |